Orexigen Therapeutics Inc. (OREX) said that the FDA advisory committee will review the company's new drug application for Contrave for the treatment of obesity on December 7, 2010.
The FDA has already set January 31, 2011 as the Prescription Drug User Fee Act action date for Contrave.
Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity.
In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.